Islet transplantation for diabetes: current status and future prospects

Bibliography

• LAPORTE RM, CHANG, Y: Prevalence and incidence of insulin dependent diabetes. (2nd edn) US Gov. Printing Office (1995).
   Google Scholar
• SUTHERLAND DE, GRUESSNERRW, GORES PF, BRAYMAN K, WAHOFF D, GRUESSNER A: Pancreas transplantation: an update. Diabet. Metab. Rev (1995) 11:337–363.
   PubMedGoogle Scholar
• SUTHERLAND DE, GORES IT, HERING BJ, WAHOFF D, MCKEEHEN DA, GRUESSNER RW: Islet transplantation: an update. Diabet. Metab. Rev (1996) 12:137–150.
   PubMed Web of Science ®Google Scholar
• GAYA SB, REES AJ, LECHLER RI, WILLIAMS G, MASON PD: Malignant disease in patients with long-term renal transplants. Transplantation (1995) 59:1705–1709.
   PubMed Web of Science ®Google Scholar
• LONDON NJ, FARMERY SM, WILL EJ, DAVISON AM, LODGE JP: Risk of neoplasia in renal transplant patients. Lancet (1995) 346:403–406.
   PubMed Web of Science ®Google Scholar
• BALISTRERI F, BUCUVALAS JC, RYCKMAN FC: The effect of immunosuppression on growth and development. Liver Transpl. Surg. (1995) 1:64–73.
   PubMedGoogle Scholar
• DRACHENBERG CB, KLASSEN DK, WEIR MR et al.: Islet cell damage associated with tacrolimus and cyclosporine: morphological features in pancreas allograft biopsies and clinical correlation. Transplantation (1999) 68:396–402.
   PubMed Web of Science ®Google Scholar
• GREMLICH S, RODUIT R,THORENS B: Dexamethasone induces post-translational degradation of GLUT2 and inhibition of insulin secretion in isolated pancreatic beta cells. Comparison with the effects of fatty acids. Biol. Chem. (1997) 272:3216–3222.
   Google Scholar
• HAHN HJ, LAUBE F, LUCKE S, KLOTING I, KOHNERT KD, WARZOCK R: Toxic effects of cyclosporin on the endocrine pancreas of Wistar rats. Transplantation (1986) 41:44–47.
   PubMed Web of Science ®Google Scholar
• RICORDI C, ZENG YJ, ALEJANDRO R et al.: In vivo effect of FK506 on human pancreatic islets. Transplantation (1991) 52:519–522.
   PubMed Web of Science ®Google Scholar
• HAUPTMAN PJ, O'CONNOR KJ: Procurement and allocation of solid organsfor transplantation. N Engl. J. Med. (1997) 336:422–431.
   PubMed Web of Science ®Google Scholar
• BENNET W, SUNDBERG B,GROTH CG et al.: Incompatibility between human blood and isolated islets of Langerhans: a finding with implications for clinical intraportal islet transplantation? Diabetes (1999) 48:1907–1914.
   Google Scholar
• NATHAN CF: Secretory products of macrophages. J. Clin. Invest. (1987) 79:319–326.
   PubMed Web of Science ®Google Scholar
• NICOLLS MR, COULOMBE M, GILL RG: The basis of immunogenicity of endocrine allografts. Grit. Rev. Immunol (2001) 21:87–101.
   PubMed Web of Science ®Google Scholar
• SUTHERLAND DE, GOETZ FC, SIBLEY RK: Recurrence of disease in pancreas transplants. Diabetes (1989) 38:85–87.
   PubMed Web of Science ®Google Scholar
• RICORDI C: Quantitative and qualitative standards for islet isolation assessment in humans and large mammals. Pancreas (1991) 6:242–244.
   PubMed Web of Science ®Google Scholar
• LAKEY JR, WARNOCK GL, RAJOTTE RV et al.: Variables in organ donors that affect the recovery of human islets of Langerhans. Transplantation (1996) 61:1047–1053.
   PubMed Web of Science ®Google Scholar
• FARNEY A, NAJARIAN J, NAKHLEH R:Autotransplantation of dispersed pancreatic islet tissue combined with total or near total pancreatectomy for treatment of chronic pancreatitis. Surgery (1991) 110:427–437.
   PubMed Web of Science ®Google Scholar
• PYZDROWSKI KL, KENDALL DM, HALTER JB, NAKHLEH RE, SUTHERLAND DE, ROBERTSON RP: Preserved insulin secretion and insulin independence in recipients of islet autografts. N Engl. J. Med. (1992) 327:220–226.
   PubMed Web of Science ®Google Scholar
• SHAPIRO AM, LAKEY JR, RYAN EA et al.: Islet transplantation in seven patients with Type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl. I Med. (2000) 343:230–238.
   PubMed Web of Science ®Google Scholar
• ••First conclusive demonstration of successful islet allografting in diabetic patients
   Google Scholar
• RYAN EA, LAKEY JR, PATY BW et al: Successful islet transplantation: continued insulin reserve provides long-term glycemic control. Diabetes (2002) 51:2148–2157.
   PubMed Web of Science ®Google Scholar
• RYAN EA, LAKEY JR, RAJOTTE RV et al.: Clinical outcomes and insulin secretion after islet transplantation with theEdmonton protocol. Diabetes (2001) 50:710–719.
   PubMed Web of Science ®Google Scholar
• GORES PF, NAJARIAN JS, STEPHANIAN E, LLOVERAS JJ, KELLEY SL, SUTHERLAND DE: Insulin independence in Type I diabetes after transplantation of unpurified islets from single donor with 15-deoxyspergualin. Lancet (1993) 341:19–21.
   PubMed Web of Science ®Google Scholar
• PLATZ KP, SOLLINGER HW, HULLETT DA, ECKHOFF DE, EUGUI EM, ALLISON AC: RS-61443 - a new, potent immunosuppressive agent. Transplantation (1991) 51:27–31.
   PubMed Web of Science ®Google Scholar
• MORRIS R: Rapamycins: antifungal, antitumor, antiproliferative and immunosuppresive macrolides. Transpl. Rev. (1992) 6:39–87.
   Google Scholar
• YAKIMETS WJ, LAKEY JR,YATSCOFF RW et al.: Prolongation of canine pancreatic islet allograft survival with combined rapamycin and cyclosporine therapy at low doses. Rapamycin efficacy is blood level related. Transplantation (1993) 56:1293–1298.
   Google Scholar
• LI Y, LI XC, ZHENG XX, WELLS AD, TURKA LA, STROM TB: Blocking both signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance. Nat. Med. (1999) 5:1298–1302.
   PubMed Web of Science ®Google Scholar
• SMILEY ST, CSIZMADIA V, GAO W, TIJRKA LA, HANCOCK WW: Differential effects of cyclosporine A, methylprednisolone, mycophenolate, and rapamycin on CD154 induction and requirement for NFkappaB: implications for tolerance induction. Transplantation (2000) 70:415–419.
   PubMed Web of Science ®Google Scholar
• NOURSE J, FIRPO E, FLANAGAN WM, et al.: Interleukin-2-mediated elimination of the p27Kipl cyclin-dependent kinase inhibitor prevented by rapamycin. Nature (1994) 372:570–573.
   Google Scholar
• POWELL JD, LERNER CG,SCHWARTZ RH: Inhibition of cell cycle progression by rapamycin induces T cell clonal anergy even in the presence of costimulation. Irnmunol. (1999) 162:2775–2784.
   PubMed Web of Science ®Google Scholar
• LEVISETTI MG, PADRID PA, SZOT GL: Immunosuppressive effects of human CTLA4Ig in a non-human primate model of allogeneic pancreatic islet transplantation. J. kifnunol. (1997) 159:5187–5191.
   Google Scholar
• BENHAMOU PY: Immunomodulation with CTL4-Ig in islet transplantation. Transplantation (2002) 73:40–42.
   Google Scholar
• •Excellent overview of immunomodulation therapy using genetically-engineered fusion proteins
   Google Scholar
• KENYON NS, CHATZIPETROU M, MASETTI M et al.: Long-term survival and function of intrahepatic islet allografts in rhesus monkeys treated with humanized anti-CD154. Proc. Nati Acad. ScL USA (1999) 96:8132–8137.
   PubMed Web of Science ®Google Scholar
• KENYON NS, FERNANDEZ LA, LEHMANN R: Long-term survival and function of intrahepatic islet allografts in baboons treated with humanized anti-CD154. Diabetes (1999) 48:1473–1481.
   PubMed Web of Science ®Google Scholar
• BUHLER L, DENG S, O'NEIL J: Adultporcine islet transplantation in baboons treated with conventional immunosuppression or a non-myeloablative regimen and CD154 blockade. Xenotransplantation (2002) 9:3–13.
   PubMed Web of Science ®Google Scholar
• LAU H, REEMTSMA K, HARDY MA: Pancreatic islet allograft prolongation by donor-specific blood transfusions treated with ultraviolet irradiation. Science (1983) 221:754–756.
   PubMed Web of Science ®Google Scholar
• RICORDI C, MURASE N, RASTELLINI C, BEHBOO R, DEMETRIS AJ, STARZL TE: Indefinite survival of rat islet allografts following infusion of donor bone marrow without cytoablation. Cell Transplant. (1996) 5:53–55.
   PubMed Web of Science ®Google Scholar
• IKEBUKURO K, ADACHI Y, YAMADA Y: Treatment of streptozotocin-induced diabetes mellitus by transplantation of islet cells plus bone marrow cells via portal vein in rats. Transplantation (2002) 73:512–518.
   PubMed Web of Science ®Google Scholar
• GAUR LK, KENNEDY E, NITTA Y: Induction of donor-specific tolerance to islet allografts in nonhuman primates. Ann. NY Acad. Sci (2002) 958:194–198.
   PubMed Web of Science ®Google Scholar
• WONG W, MORRIS PJ, WOOD KJ: Pretransplant administration of a single donor class I major histocompatibility complex molecule is sufficient for the indefinite survival of fully allogeneic cardiac allografts: evidence for linked epitope suppression. Transplantation (1997) 63:1490–1494.
   PubMed Web of Science ®Google Scholar
• YANG L, DUTEMPLE B,GORCZYNSKI RM, LEVY G, ZHANG L: Evidence for epitope spreading and active suppression in skin graft tolerance after donor-specific transfusion. Transplantation(1999) 67:1404–1410.
   PubMed Web of Science ®Google Scholar
• BRENNAN DC, MOHANAKUMAR T, FLYE MW: Donor-specific transfusion and donor bone marrow infusion in renal transplantation tolerance: a review of efficacy and mechanisms. Am. J. Kid. Dit(1995) 26:701–715.
   PubMed Web of Science ®Google Scholar
• HEROLD KC, HAGOPIAN W, AUGER JA et al.: Anti-CD3 monoclonal antibody in new-onsetType I diabetes mellitus. N Engl. I Med. (2002) 346:1692–1698.
   PubMed Web of Science ®Google Scholar
• ••Clinical demonstration of use of an anti-CD3 mAb to slow the progression of Type I diabetes.
   Google Scholar
• LENS CHOW DJ, ZENG Y, THISTLETHWAITE JR et al.: Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA41g. Science (1992) 257:789–792.
   PubMed Web of Science ®Google Scholar
• LENS CHOW DJ, ZENG Y, HATHCOCK KS et al: Inhibition of transplant rejection following treatment with anti-B7-2 and anti-B7-1 antibodies. Transplantation (1995) 60:1171–1178.
   PubMed Web of Science ®Google Scholar
• GREWAL IS, XU J, FLAVELL RA: Impairment of antigen-specific T-cell priming in mice lacking CD40 ligand. Nature (1995) 378:617–620.
   PubMed Web of Science ®Google Scholar
• RIDGE JP, DI ROSA F, MATZINGER R A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature (1998) 393:474–478.
   PubMed Web of Science ®Google Scholar
• KIRK AD, HARLAN DM,ARMSTRONG NN et al.: CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc. Natl Acad. Sci. USA (1997) 94:8789–8794.
   Google Scholar
• KOVER KL, GENG Z, HESS DM, BENJAMIN CD, MOORE WV: Anti-CD154 (CD4OL) prevents recurrence of diabetes in islet isografts in the DR-BB rat. Diabetes (2000) 49: 1666-1670.
   Google Scholar
• MOLANO RD, BERNEY T, LI H et al:Prolonged islet graft survival in NOD mice by blockade of the CD4O-CD154 pathway of T-cell costimulation. Diabetes (2001) 50:270–276.
   PubMed Web of Science ®Google Scholar
• LEHNERT AM, MOTTRAN PL, HAN W et al.: Blockade of the CD28 and CD40 pathways result in the acceptance of pig and rat islet xenografts but not rat cardiac grafts in mice. Transpl. Innnunel (2001) 9:51–56.
   Google Scholar
• BENNET W, SUNDBERG B, LUNDGREN T et al.: Damage to porcine islets of Langerhans after exposure to human blood M vitro, or after intraportal transplantation to cynomologus monkeys: protective effects of sCR1 and heparin. Transplantation (2000) 69:711–719.
   PubMed Web of Science ®Google Scholar
• THOMAS JM, CONTRERAS JL, SMYTH CA et al.: Successful reversal of streptozotocin-induced diabetes with stable allogeneic islet function in a preclinical model of Type I diabetes. Diabetes (2001) 50:1227–1236.
   PubMed Web of Science ®Google Scholar
• LUMELSKY N, BLONDEL 0, LAENG P,VELASCO I, RAVIN R, MCKAY R: Differentiation of embryonic stem cells to insulin-secreting structures similar to pancreatic islets. Science (2001) 18:1389–1394.
   Google Scholar
• •Demonstrates that mouse embryonic cells can be differentiated in insulin-producing islet-like structures.
   Google Scholar
• SORIA, B, ROCH EE, BERNA G, LEON-QUINTO T, REIG JA, MARTIN F: Insulin secreting cells derived from embryonic stem cells normalize glycemia in streptozotocin-induced diabetic mice. Diabetes (2000) 49:157–162.
   PubMed Web of Science ®Google Scholar
• •Genetically-engineered mouse cells produce insulin and reverse diabetes when transplanted into mice.
   Google Scholar
• ASSADY S, MAOR G, AMIT M, ITSKOVITZ-ELDOR J, SKORTCKI KL, TZUKERMAN M: Insulin production by human embryonic stem cells. Diabetes (2001) 50:1691–1697.
   PubMed Web of Science ®Google Scholar
• SCHULDER J, YANUKA 0, ITSKOVITZ-ELDOR J, MELTON D, BENVENISTY N: Effects of eight growth factors on the differentiation of cells derived from human embryonic stem cells. Proc. Nati Acad. Sci. USA(2000) 97:11307–11312.
   PubMedGoogle Scholar
• RAMIYA VK, MARAIST M, ARFORS KE, SCHATZ DA, PECK AB, CORNELIUS JG: Reversal of insulin-dependent diabetes using islets generated M vitro from pancreatic stem cells. Nat. Med. (2000) 6:278–282.
   PubMed Web of Science ®Google Scholar
• •Raises the possibility of generating islets from ductal stem cells.
   Google Scholar
• BONNER-WEIR S, TANEJA M, WEIR GC et al.: ha vitro cultivation of human islets from expanded ductal tissue. Proc. Natl. Acad. Sci. USA (2000) 97:7999–8004.
   PubMed Web of Science ®Google Scholar
• •Demonstrates feasibility of generating endocrine and ductal cells from adult human sources.
   Google Scholar
• ZULEWSKI H, ABRAHAM EJ, GERALCH MJ: Multipotential nestin-positive stem cells isolated from adult pancreatic islets differentiate ex vivo into pancreatic endocrine, exocrine, and hepatic phenotypes. Diabetes (2001) 50:521–533.
   PubMed Web of Science ®Google Scholar
• LECHNER A, LEECH CA, ABRAHAM EJ, NOLAN AL, HABENER JF: Nestin-positive progenitor cells derived from adult human pancreatic islets of Langerhans contain side population (SP) cells defined by expression of the ABCG2 (BCRP1) ATP-binding cassette transporter. Biochem. Biophy Res. Commun. (2002) 293:670–674.
   PubMed Web of Science ®Google Scholar
• GU G, DUBAUSKAITE J, MELTON DA: Direct evidence for the pancreatic lineage: NGN3+ cells are islet progenitors and are distinct from duct progenitors. Development (2002) 129:2447–2457.
   PubMed Web of Science ®Google Scholar
• •Clear evidence of islet progenitors as opposed to other cells that can be coaxed to form islet like progenitors.
   Google Scholar
• DE VOS P, HAMEL AF, TATARKIEWICZ K: Considerations for successful transplantation of encapsulated pancreatic islets. Diabetologia (2002) 45:159–173.
   PubMed Web of Science ®Google Scholar
• GRAY DW: An overview of the immune system with specific reference to membrane encapsulation and islet transplantation. Ann. NY Acad. Sci. (2001) 944:226–239.
   PubMed Web of Science ®Google Scholar
• •Good overview of immunoisolation technologies.
   Google Scholar
• SUN AM, O& SHEA GM, GOOSEN MF: Injectable microencapsulated islet cells as a bioartificial pancreas. Appl Biochem. Biotechnol (1984) 10:87–99.
   PubMed Web of Science ®Google Scholar
• LANZA RP, ECKER DM, KUHTREIBER WM, MARSH JP, RINGELING J, CHICK WL: Transplantation of islets using microencapsulation: studies in diabetic rodents and dogs. J. MM. Med. (1999) 77:206–210.
   PubMed Web of Science ®Google Scholar
• LACY PE: Treating diabetes with transplanted cells. Sci. Amer (1995) 273:50–58.
   PubMed Web of Science ®Google Scholar
• SUN Y, MAX, ZHOU D, VACEK I, SUN AM: Normalization of diabetes in spontaneously diabetic cynomologus monkeys by xenografts of microencapsulated porcine islets without immunosuppression. I Clin. Invert. (1996) 98:1417–1422.
   PubMed Web of Science ®Google Scholar
• SOON-SHIONG P, HEINTZ RE, MERIDETH N et al.: Insulin independence in a Type 1 diabetic patient after encapsulated islet transplantation. Lancet (1994) 343:950–951.
   PubMed Web of Science ®Google Scholar
• GRAY DW: Encapsulated islet cells: the role of direct and indirect presentation and the relevance to xenotransplantation and autoimmune recurrence. Br. Med. Bull. (1997) 53:777–788.
   PubMed Web of Science ®Google Scholar
• SELAWRY HP: Islet transplantation to immunoprivileged sites. In: Pancreatic Islet Transplantation Volume II: Immunomodulation of Pancreatic Islets Lanza RP & Chick WL (Eds.), CRC Press, Boca Raton, FL (1994) 75–86.
   Google Scholar
• SELAWRY HP, WHITTINGTON K: Extended allograft survival of islets grafted into intra-abdominally placed testes. Diabetes (1984) 33:405–406.
   PubMed Web of Science ®Google Scholar
• SELAWRY HP, WHITTINGTON KB, BELLGRAU D: Abdominal intratesticular islet-xenograft survival in rats. Diabetes (1989) 38:220–223.
   PubMed Web of Science ®Google Scholar
• SELAWRY HP, GABER AO: Intratesticular islet allograft survival in the Rhesus monkey without sustained immunosuppression. Cell Transpl (In Press).
   Google Scholar
• GORES P, FIELD J, RAJOTTE R, KORBUTT G: Extended xenogeneic grafts in the abdominal testes in dogs. Transplantation (In Press).
   Google Scholar
• CAMERON DF, WHITTINGTON K, SCHULTZ RE, SELAWRY HP: Successful islet/abdominal testes transplantation does not require Leydig cells. Transplantation (1990) 50:649–653.
   PubMed Web of Science ®Google Scholar
• SELAWRY HP, CAMERON DF: Sertoli cell-enriched fractions in successful islet transplantation. Cell Transpl. (1993) 2:123–129.
   PubMed Web of Science ®Google Scholar
• •Seminal demonstration that isolated Sertoli cells can be grafted into an ectopic site and provide local irnmunoprotection.
   Google Scholar
• KORBUTT GS, ELLIOTT JF, RAJOTTE RV: Cotransplantation of allogeneic islets with allogeneic testicular cell aggregates allows long-term graft survival without systemic immunosuppression. Diabetes (1997) 46:317–322.
   PubMed Web of Science ®Google Scholar
• KORBUTT GS, SUAREZ-PINZON W, POWER RF, RAJOTTE RV, RABINOVITCH A: Testicular Sertoli cells exert both protective and destructive effects on syngeneic islet grafts in non-obesediabetic mice. Diabetologia (2000) 43:474–480.
   PubMed Web of Science ®Google Scholar
• SUAREZ-PINZON W, KORBUTT GS, POWER R, HOOTON J, RAJOTTE RV, RABINOVITCH A: Testicular Sertoli cells protect islet 13 cells from autoimmune destruction in NOD mice by a transforming growth factor-131-mechanism. Diabetes (2000) 49: 1810-1818.
   Google Scholar
• VALDES-GOMZALAEZ RA,ELLIOT RB, DORANTES LM et al: Porcine islet xenografts can survive and function in Type I diabetic patients in the presence of both pre-existing and elicited anti-pig antibodies. Transplantation Sapp]. (2002) 74:94.
   Google Scholar
• •Preliminary but interesting initial report of potential of xenotransplantion in diabetics using pig Sertoli cells together with pig islets.
   Google Scholar
• MCKENZIE IFC, D'APICE AJF, COOPER DKC: Xenotransplantation trials. Lancet (2002) 359:2280–2281.
   Web of Science ®Google Scholar
• WELSH N: Gene therapy in diabetes mellitus: promises and pitfalls. Carr: Opin. MM. Ther. (1999) 1:464–470.
   PubMed Web of Science ®Google Scholar
• •Good overview of potential of gene therapy in diabetes.
   Google Scholar
• EFRAT S, FUSCO-DEMANE D, LEMBERG H, AL EMRAN 0, WANG X: Conditional transformation of a pancreatic beta-cell line derived from transgenic mice expressing a tetracycline-regulated oncogene. Proc. Nati Acad. ScL USA (1995) 92:3576–3580.
   PubMed Web of Science ®Google Scholar
• EFRAT S, LEISER M, SURANA M, TAL M, FUSCO-DEMANE D, FLEISCHER N: Murine insulinoma cell line with normal glucose-regulated insulin secretion. Diabetes (1993) 42:901–907.
   PubMed Web of Science ®Google Scholar
• KNAACK D, FIORE DM, SURANA M et al.: Clonal insulinoma cell line that stably maintains correct glucose responsiveness. Diabetes (1994) 43:1413–1417.
   PubMed Web of Science ®Google Scholar
• SOLDEVILA G, BUSCEMA M, MARINI V: Transfection with 5V40 gene of human pancreatic endocrine cells. Autoimmun. (1991) 4:381–396.
   Web of Science ®Google Scholar
• WANG S, BEATTIE GM, MALLY MI, LOPEZ AD, HAYEK A, LEVINE F: Analysis of a human fetal pancreatic islet cell line. Transpl. Proc. (1997) 29:2219.
   PubMed Web of Science ®Google Scholar
• DE LA TOUR D, HALVORSEN T, DEMETERCO CF et al.: 13-cell differentiation from a human pancreatic cell line in vitro and in vivo. MM. Endocrin. (2001) 15:476–83.
   Google Scholar
• WANG S, BEATTIE GM, MALLY MI et al.: Isolation and characterization of a cell line from the epithelial cells of the human fetal pancreas. Cell Transpl. (1997) 6:59–67.
   PubMed Web of Science ®Google Scholar
• HALVORSEN TL, LEIBOWITZ G, LEVINE F: Telomerase activity is sufficient to allow transformed cells to escape from crisis. Ma Cell Biol. (1999) 19:1864–1870.
   Web of Science ®Google Scholar
• ITKIN-ANSARI P, DEMETERCO C, BOSSIE S et al.: PDX-1 and cell-cell contact act in synergy to promote d-cell development in a human pancreatic endocrine precursor cell line. Ma Endocrin. (2000) 14:814–822.
   PubMed Web of Science ®Google Scholar
• EFRAT S, FUSCO-DEMANE D, LEMBERG H, AL EMRAN 0, WANG X: Conditional transformation of a pancreatic beta-cell line derived from transgenic mice expressing a tetracycline-regulated oncogene. Proc. Natl. Acad. Sci. USA (1995) 92:3576–3580.
   PubMed Web of Science ®Google Scholar
• FLEISCHER N, CHEN C, SURANA M et al.: Functional analysis of a conditionally transformed pancreatic beta-cell line. Diabetes (1998) 47:1419–1425.
   PubMed Web of Science ®Google Scholar
• MCCURRY KR, KOOYMAN DL, ALVARADO CG et al: Humancomplement regulatory proteins protect swine-to-primate cardiac xenografts from humoral injury. Nat. Med. (1995) 1:423–427.
   PubMed Web of Science ®Google Scholar
• TEARLE RG, TANGE MJ,ZANNETTINO ZL et al.: The alpha-13-galactosyltransferase knockout mouse. Implications for xenotransplantation. Transplantation (1996) 61:13–19.
   Google Scholar
• ••Sunurtarised potential of potential ofgenetically-engineering donor tissue to facilitate xenograft acceptance.
   Google Scholar
• COWAN PJ, CHEN CG, SHINKEL TA et al: Knock out of alphal,3-galactosyltransferase or expression of alphal, 2- fucosyltransferase further protects CD55- and CD59-expressing mouse hearts in an ex vivo model of xenograft rejection. Transplantation (1998) 65: 1599-1604.
   Google Scholar
• STOYE J: No clear answers on safety of pigs as tissue donor source. Lancet (1998) 352:666–667.
   PubMed Web of Science ®Google Scholar
• STOYE JP, COFFIN JM: The dangers ofxenotransplantation. Nat. Med. (1995) 1:1100.
   PubMed Web of Science ®Google Scholar
• •Summary of safety concerns with xenotransplantation.
   Google Scholar
• PARADIS K, LANGFORDG, LONG Z et al.: Search for cross-species transmission of porcine endogenous retrovirus in patients treated with living pig tissue. Science (1999) 285:1236–1241
   PubMed Web of Science ®Google Scholar
• •Important overview of lack of PERV transmission in vivo.
   Google Scholar
• WEISS RA: Xenografts and retroviruses. Science (1999) 285:1221–1222.
   PubMed Web of Science ®Google Scholar
• GROTH CG, KORSGREN 0, TIBELL A et al.: Transplantation of porcine fetal pancreas to diabetic patients. Lancet (1994) 344:1402–1404.
   Google Scholar
• HENEINE W, TIBELL A, SWITZER WM et al.: No evidence of infection with porcine endogenous retrovirus in recipients of porcine islet-cell xenografts. Lancet (1998) 352:695–699.
   PubMed Web of Science ®Google Scholar